Rochester Network Lead Academic Participating Site

罗切斯特网络领导学术参与网站

• 批准号: 9889075
• 负责人: Paul M Barr
• 金额: $ 68.63万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-07 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9889075
• 关键词: Achievement; Adult; Award; Cancer Biology; Clinical; Clinical Trials; Committee Membership; Communities; Complex; Conduct Clinical Trials; Correlative Study; Country; Data; Dedications; Development; Discipline of obstetrics; Disease; Eastern Cooperative Oncology Group; Elderly; Enrollment; Ensure; Faculty; Funding; Genitourinary system; Goals; Gynecologic Oncology; Gynecology; Health; Hematology; Institutes; Institution; Investments; Laboratory Research; Lead; Leadership; Lymphoma; Malignant - descriptor; Malignant Neoplasms; Medical Oncology; Medicine; Mentors; Minority; Mission; Multiple Myeloma; National Clinical Trials Network; Oncology; Operative Surgical Procedures; Patients; Phase; Population; Positioning Attribute; Prevention; Protocols documentation; Publications; Radiation Oncology; Rare Diseases; Recording of previous events; Research; Research Activity; Research Institute; Research Personnel; Role; Site; Southwest Oncology Group; Structure; Surgical Oncology; Time; Tissues; Underrepresented Populations; Universities; Urology; Work; base; cancer clinical trial; community based practice; data management; gastrointestinal; improved outcome; leukemia; member; multidisciplinary; novel therapeutics; oncology program; performance site; programs; rare cancer; success; therapy outcome; working group; young adult

PROJECT SUMMARY/ABSTRACT The University of Rochester, Wilmot Cancer Institute is a health and research institute ideally suited to achieve the goals of the NCI NCTN as a Lead Academic Site. Our longstanding activity as U10-funded members of ECOG (1968-2002) and SWOG (2002-2012) as well as our dedication to NCTN trials over the past 5 years indicate our continued investment in and commitment to clinical and translational laboratory research in cancer, particularly the development of and accrual to late-phase Cancer Clinical Trials. In an era where both the biology of cancer and development of novel therapeutic strategies have become more complex, requiring multidisciplinary teams of investigators and extensive tissue banking and correlative studies, our translational scientific program and dedication to the NCTN program is critical for ultimate success. Our Clinical Trials Program consists of a leadership group and faculty across the departments of medicine (hematology and medical oncology), surgery, urology, radiation oncology and obstetrics and gynecology who are highly invested in the NCTN program. The NCTN trials structure is a key component of our Clinical Trials Office, and utilizes multidisciplinary disease Working Groups as the hub for protocol management, ensuring appropriate and broad-based expertise. Our leadership roles within the NCTN groups, committee membership, publication record, and scientific achievements position us well for continued quality contributions to the ultimate mission of NCTN. We have a long history of coordinating cooperative group studies and continue to do so, building on preliminary work conducted at University of Rochester but also collaborating across all of the US based NCTN groups. Between 2014 and 2017, we were able to activate NCTN clincal trials quickly, accrued more than 100 patients annually on average, and submitted high quality data in an efficient manner. As such, Rochester was recogized as a High Performing Site by the NCI. We plan to further increase this effort across the Network given our expanded regional presence, while continuing to focus on underrepresented patient groups including the adolesent/young adult and geriatric populations. We have led the country in accrual to several important studies, including studies conducted on rare diseases, and our efforts to enhance minority accrual have resulted in accrual to clinical trials representative of our overall population. The University of Rochester is dedicated to the mission of the NCTN and will continue to contibute to the development and conduct of associated trials at the highest level.

项目概要/摘要 罗切斯特大学威尔莫特癌症研究所是一所非常适合实现以下目标的健康和研究机构 NCI NCTN 作为领先学术网站的目标。我们作为 U10 资助的成员的长期活动 ECOG (1968-2002) 和 SWOG (2002-2012) 以及我们过去 5 年对 NCTN 试验的奉献 表明我们对癌症临床和转化实验室研究的持续投资和承诺， 特别是晚期癌症临床试验的发展和积累。在一个生物学与 癌症的研究和新治疗策略的开发变得更加复杂，需要 多学科研究团队和广泛的组织库和相关研究，我们的转化 科学计划和对 NCTN 计划的奉献对于最终成功至关重要。 我们的临床试验计划由跨医学部门的领导小组和教职员工组成 （血液科和肿瘤内科）、外科、泌尿科、放射肿瘤科和妇产科谁 对 NCTN 项目投入了大量资金。 NCTN 试验结构是我们临床试验的关键组成部分 办公室，并利用多学科疾病工作组作为方案管理中心，确保 适当且基础广泛的专业知识。我们在 NCTN 团体中的领导角色、委员会成员身份、 出版记录和科学成就使我们能够继续为最终的高质量贡献 NCTN 的使命。我们在协调合作小组研究方面有着悠久的历史，并将继续这样做， 以罗切斯特大学开展的初步工作为基础，同时也在美国各地进行合作 NCTN 团体。 2014年至2017年间，我们能够快速启动NCTN临床试验，累计超过100名患者 平均每年一次，并高效地提交高质量的数据。就这样，罗切斯特被认可了。 被 NCI 评为高性能站点。鉴于我们的情况，我们计划在整个网络上进一步加大力度 扩大区域影响力，同时继续关注代表性不足的患者群体，包括 青少年/年轻人和老年人群。我们带领国家进行了几项重要的研究， 包括对罕见疾病进行的研究，以及我们为加强少数群体应计所做的努力已取得 代表我们总体人群的临床试验的应计费用。罗切斯特大学致力于 NCTN 的使命，并将继续为相关试验的开发和开展做出贡献 最高级别。